1,567
27
Essay, 1 pages (250 words)

Corrigendum: blood-based dna methylation biomarkers for type 2 diabetes: potential for clinical applications

A Corrigendum on
Blood-Based DNA Methylation Biomarkers for Type 2 Diabetes: Potential for Clinical Applications

by Willmer, T., Johnson, R., Louw, J., and Pheiffer, C. (2018). Front. Endocrinol. 9: 744. doi: 10. 3389/fendo. 2018. 00744

In the original article, there was an error. “ Colombian” was misspelled as “ Columbian.”

A correction has been made to theIntroduction, Global DNA Methylation Studies, paragraph two.

“ Luttmer et al. quantified global DNA methylation levels in peripheral blood leukocytes of 738 individuals from the Netherlands Hoorn Study cohort and reported a progressive decrease in global DNA methylation in individuals with T2D compared to those with impaired glucose tolerance and normoglycaemia. Moreover, DNA hypomethylation in these subjects was independently associated with hyperglycaemia and high-density lipoprotein (HDL) cholesterol (28). In contrast, a Colombian study using a smaller patient group, observed a global increase in DNA methylation in 44 subjects with T2D compared to 35 healthy controls, which correlated with the percentage of glycated hemoglobin A1c (HbA1c) (29). Similar findings were reported by Matsha et al. using a South African population consisting of 158 individuals with T2D, 119 with dysglycaemia, and 287 healthy controls. They showed that levels of global DNA methylation were higher in individuals with impaired glucose tolerance or treatment-naïve T2D compared to those with normoglycaemia (29, 30). Interestingly, no difference in global DNA methylation was observed between diabetic individuals on treatment and normoglycaemic subjects, prompting the authors to speculate that glucose management caused the reversal of aberrant DNA methylation patterns during T2D (30).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Thank's for Your Vote!
Corrigendum: blood-based dna methylation biomarkers for type 2 diabetes: potential for clinical applications. Page 1
Corrigendum: blood-based dna methylation biomarkers for type 2 diabetes: potential for clinical applications. Page 2
Corrigendum: blood-based dna methylation biomarkers for type 2 diabetes: potential for clinical applications. Page 3

This work, titled "Corrigendum: blood-based dna methylation biomarkers for type 2 diabetes: potential for clinical applications" was written and willingly shared by a fellow student. This sample can be utilized as a research and reference resource to aid in the writing of your own work. Any use of the work that does not include an appropriate citation is banned.

If you are the owner of this work and don’t want it to be published on AssignBuster, request its removal.

Request Removal
Cite this Essay

References

AssignBuster. (2022) 'Corrigendum: blood-based dna methylation biomarkers for type 2 diabetes: potential for clinical applications'. 3 August.

Reference

AssignBuster. (2022, August 3). Corrigendum: blood-based dna methylation biomarkers for type 2 diabetes: potential for clinical applications. Retrieved from https://assignbuster.com/corrigendum-blood-based-dna-methylation-biomarkers-for-type-2-diabetes-potential-for-clinical-applications/

References

AssignBuster. 2022. "Corrigendum: blood-based dna methylation biomarkers for type 2 diabetes: potential for clinical applications." August 3, 2022. https://assignbuster.com/corrigendum-blood-based-dna-methylation-biomarkers-for-type-2-diabetes-potential-for-clinical-applications/.

1. AssignBuster. "Corrigendum: blood-based dna methylation biomarkers for type 2 diabetes: potential for clinical applications." August 3, 2022. https://assignbuster.com/corrigendum-blood-based-dna-methylation-biomarkers-for-type-2-diabetes-potential-for-clinical-applications/.


Bibliography


AssignBuster. "Corrigendum: blood-based dna methylation biomarkers for type 2 diabetes: potential for clinical applications." August 3, 2022. https://assignbuster.com/corrigendum-blood-based-dna-methylation-biomarkers-for-type-2-diabetes-potential-for-clinical-applications/.

Work Cited

"Corrigendum: blood-based dna methylation biomarkers for type 2 diabetes: potential for clinical applications." AssignBuster, 3 Aug. 2022, assignbuster.com/corrigendum-blood-based-dna-methylation-biomarkers-for-type-2-diabetes-potential-for-clinical-applications/.

Get in Touch

Please, let us know if you have any ideas on improving Corrigendum: blood-based dna methylation biomarkers for type 2 diabetes: potential for clinical applications, or our service. We will be happy to hear what you think: [email protected]